Balancing toxicity and efficacy: learning from trials and treatment using antiresorptive therapy in prostate cancer.
The Christie and Salford Royal Hospitals, Manchester, UK. Electronic address: noel.clarke@srft.nhs.uk.
Noel W
NW
Clarke
D000726:Androgen Antagonists / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D050071:Bone Density Conservation Agents / Q000009:adverse effects*; D001859:Bone Neoplasms / Q000188:drug therapy*; D000069448:Denosumab; D004164:Diphosphonates / Q000009:adverse effects*; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects*; D008297:Male; D010010:Osteoclasts / Q000187:drug effects*; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D053245:RANK Ligand / Q000037:antagonists & inhibitors*; D000077211:Zoledronic Acid
D000726:Androgen Antagonists; D061067:Antibodies, Monoclonal, Humanized; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D053245:RANK Ligand; C505688:TNFSF11 protein, human; D000069448:Denosumab; D000077211:Zoledronic Acid